{"id":"posaconazole-oral-suspension","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-15","effect":"Elevated liver enzymes"},{"rate":"2-5","effect":"Hypokalemia"}]},"_chembl":{"chemblId":"CHEMBL1397","moleculeType":"Small molecule","molecularWeight":"700.79"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a triazole antifungal, posaconazole binds to the cytochrome P450-dependent enzyme lanosterol 14α-demethylase in fungi, preventing the conversion of lanosterol to ergosterol. This disrupts the fungal cell membrane structure, leading to cell lysis and fungal death. The oral suspension formulation provides improved bioavailability compared to earlier formulations.","oneSentence":"Posaconazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting fungal cell wall integrity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:47.041Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients"},{"name":"Treatment of oropharyngeal candidiasis"},{"name":"Treatment of invasive fungal infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT04665037","phase":"PHASE2","title":"Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-02-22","conditions":"Invasive Fungal Infection","enrollment":40},{"nctId":"NCT01420562","phase":"","title":"Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2011-09","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":55},{"nctId":"NCT04194086","phase":"PHASE1, PHASE2","title":"Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2018-11-01","conditions":"Leukemia, Acute","enrollment":42},{"nctId":"NCT04966234","phase":"PHASE2, PHASE3","title":"A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-04-22","conditions":"Cystic Fibrosis, Aspergillosis","enrollment":135},{"nctId":"NCT00799071","phase":"PHASE2","title":"Pharmacokinetics of Posaconazole in Children With Chronic Granulomatous Disease (CGD)","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-02","conditions":"Chronic Granulomatous Disease","enrollment":12},{"nctId":"NCT03336502","phase":"PHASE1","title":"Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-12-20","conditions":"Fungal Infection","enrollment":70},{"nctId":"NCT02452034","phase":"PHASE1","title":"Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-07","conditions":"Neutropenia","enrollment":118},{"nctId":"NCT03614455","phase":"EARLY_PHASE1","title":"Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2018-07-13","conditions":"Pharmacokinetics","enrollment":36},{"nctId":"NCT00686621","phase":"","title":"Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)","status":"APPROVED_FOR_MARKETING","sponsor":"Merck Sharp & Dohme LLC","startDate":"","conditions":"Mycoses","enrollment":""},{"nctId":"NCT01377480","phase":"PHASE2","title":"A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07-06","conditions":"Chagas Disease","enrollment":120},{"nctId":"NCT01716234","phase":"PHASE1","title":"A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-04-17","conditions":"Fungal Infections","enrollment":142},{"nctId":"NCT03631602","phase":"PHASE2, PHASE3","title":"Posaconazole vs Itraconazole in Preventing IFD Post-HSCT","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2017-10-01","conditions":"IFD Post-HSCT","enrollment":120},{"nctId":"NCT01075984","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-02-23","conditions":"Fungal Infection","enrollment":279},{"nctId":"NCT00423267","phase":"PHASE3","title":"POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"Coccidioidomycosis","enrollment":16},{"nctId":"NCT00811642","phase":"PHASE3","title":"Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11","conditions":"Fungal Infection","enrollment":63},{"nctId":"NCT00811928","phase":"PHASE3","title":"Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-11","conditions":"Leukopenia","enrollment":252},{"nctId":"NCT00491764","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":"Onychomycosis","enrollment":218},{"nctId":"NCT00550732","phase":"PHASE2","title":"A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Mycoses","enrollment":40},{"nctId":"NCT00034632","phase":"PHASE3","title":"Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-04","conditions":"Mycoses","enrollment":""},{"nctId":"NCT00034645","phase":"PHASE3","title":"Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"1999-01","conditions":"Mycoses","enrollment":600},{"nctId":"NCT00044486","phase":"PHASE3","title":"Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-07","conditions":"Leukemia, Myelocytic, Acute, Myelodysplastic Syndromes, Neutropenia","enrollment":602},{"nctId":"NCT00034671","phase":"PHASE2","title":"PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":"Mycoses","enrollment":98},{"nctId":"NCT01436578","phase":"","title":"Safety and Efficacy of Posaconazole Oral Suspension in Usual Practice in Korea (P08547)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02","conditions":"Fungal Infections","enrollment":273},{"nctId":"NCT00002446","phase":"PHASE3","title":"Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients","status":"COMPLETED","sponsor":"Schering-Plough","startDate":"1998-08","conditions":"Candidiasis, Oral, HIV Infections","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":79,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MK-5592","SCH 056592","Noxafil®"],"phase":"phase_3","status":"active","brandName":"Posaconazole oral suspension","genericName":"Posaconazole oral suspension","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Posaconazole inhibits fungal cell membrane ergosterol synthesis by blocking lanosterol 14α-demethylase, disrupting fungal cell wall integrity. Used for Prophylaxis of invasive Aspergillus and Candida infections in high-risk immunocompromised patients, Treatment of oropharyngeal candidiasis, Treatment of invasive fungal infections in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}